Artificial intelligence and endo-histo-omics: new dimensions of precision endoscopy and histology in inflammatory bowel disease

Simple item page
dc.contributor.authorIacucci, Mariettaen
dc.contributor.authorSantacroce, Giovannien
dc.contributor.authorZammarchi, Ireneen
dc.contributor.authorMaeda, Yasuharuen
dc.contributor.authorDel Amor, RocĂ­oen
dc.contributor.authorMeseguer, Pabloen
dc.contributor.authorKolawole, Bisi Bodeen
dc.contributor.authorChaudhari, Ujwalaen
dc.contributor.authorDi Sabatino, Antonioen
dc.contributor.authorDanese, Silvioen
dc.contributor.authorMori, Yuichien
dc.contributor.authorGrisan, Enricoen
dc.contributor.authorNaranjo, Valeryen
dc.contributor.authorGhosh, Subrataen
dc.date.accessioned2025-01-24T12:35:45Z
dc.date.available2025-01-24T12:35:45Z
dc.date.issued2024-07-03en
dc.description.abstractIntegrating artificial intelligence into inflammatory bowel disease (IBD) has the potential to revolutionise clinical practice and research. Artificial intelligence harnesses advanced algorithms to deliver accurate assessments of IBD endoscopy and histology, offering precise evaluations of disease activity, standardised scoring, and outcome prediction. Furthermore, artificial intelligence offers the potential for a holistic endo-histo-omics approach by interlacing and harmonising endoscopy, histology, and omics data towards precision medicine. The emerging applications of artificial intelligence could pave the way for personalised medicine in IBD, offering patient stratification for the most beneficial therapy with minimal risk. Although artificial intelligence holds promise, challenges remain, including data quality, standardisation, reproducibility, scarcity of randomised controlled trials, clinical implementation, ethical concerns, legal liability, and regulatory issues. The development of standardised guidelines and interdisciplinary collaboration, including policy makers and regulatory agencies, is crucial for addressing these challenges and advancing artificial intelligence in IBD clinical practice and trials.en
dc.description.statusPeer revieweden
dc.description.versionAccepted Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.citationIacucci, M., Santacroce, G., Zammarchi, I., Maeda, Y., Del Amor, R., Meseguer, P., Kolawole, B. B., Chaudhari, U., Di Sabatino, A., Danese, S. and Mori, Y. (2024) 'Artificial intelligence and endo-histo-omics: new dimensions of precision endoscopy and histology in inflammatory bowel disease', The Lancet Gastroenterology & Hepatology, 9(8), pp. 758-772. https://doi.org/10.1016/S2468-1253(24)00053-0en
dc.identifier.doihttps://doi.org/10.1016/S2468-1253(24)00053-0en
dc.identifier.endpage772en
dc.identifier.issn2468-1253en
dc.identifier.issued8en
dc.identifier.journaltitleThe Lancet Gastroenterology & Hepatologyen
dc.identifier.startpage758en
dc.identifier.urihttps://hdl.handle.net/10468/16889
dc.identifier.volume9en
dc.language.isoenen
dc.publisherElsevier Ltd.en
dc.rights© 2024, Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies. This manuscript version is made available under the CC BY-NC-ND 4.0 license.en
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en
dc.subjectArtificial intelligenceen
dc.subjectInflammatory bowel disease (IBD)en
dc.titleArtificial intelligence and endo-histo-omics: new dimensions of precision endoscopy and histology in inflammatory bowel diseaseen
dc.typeArticle (peer-reviewed)en
oaire.citation.issue8en
oaire.citation.volume9en
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Lancet Revised_R2_clean.docx
Size:
95.03 KB
Format:
Microsoft Word XML
Description:
Accepted Version
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
APC Microbiome Ireland - Journal Articles